Loading
A phase 1/2 trial of PRJ1-3024 in melanoma, run by Zhuhai Yufan Biotechnologies Co., Ltd, now recruiting.
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06727630 by Zhuhai Yufan Biotechnologies Co., Ltd, with 40 participants planned, started 2024-03-14 and due to reach its primary completion in 2025-04-30. Interventions recorded: PRJ1-3024.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zhuhai Yufan Biotechnologies and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/